Resproly Completed 50 Million yuan A Round of Financing

On August 29, medical device developer Resproly completed 50 million yuan A round of financing. This round of financing was invested by Huaige Capital, Gree Investments, Yanghe Investments, and Kangdelai.

Resproly will use the funding to complete the construction of the workshop in Zhuhai and purchased high-end equipment in Germany. In addition, Resproly will submit the clinical application of new products and expand the team size.

Founded in 2018, Resproly is a medical device company. The company is registered in Jinwan District, Zhuhai, with 650 square meters of research and development office environment and 5400 square meters of production workshop. The company was founded by the doctor of University of Cambridge, pharmaceutical expert of GSK, and president of Shenzhen Life Science and Biotechnology Association. Resproly's business includes development, production, and sales of respiratory system inhalation drug delivery device. Resproly aims to be a leader in the field of the respiratory system.

Resproly's products includes Metered Dose Inhaler (MDI), Dry Powder Inhaler (DPI), Nebulizer and Nasal Spray. The products involve a lot of clinical fields, including asthma, COPD, diabetes, Parkinson's disease, etc. Resproly has the core technology of inhalation drug delivery device and the ability to develop new bio-antibody inhalation drug delivery device. Its online products cover several drugs on the top of the Blockbuster Drug List. 

Huaige Capital is a Chinese investment company focused on the field of healthcare.

Founded in 2017, Gree Investments is a subsidiary corporation of Gree focused on the field of the manufacturing industry.

Founded in 2013, Yanghe Investments is an investment company jointly established by Yangpu Medical and Hejia Medical.

Founded in 1995, Kangdelai is a medical device company with 500 employees.